Drug Trial Radar · NCT02446912
Efficacy and Safety of Two Doses of Anifrolumab Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus
Last checked: Nov 20, 2026Latest source record: Jan 12, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
460
Actual
Start
Jun 9, 2015
Primary completion
Jul 17, 2018
Study completion Jul 17, 2018
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- Collaborators
- PRA Health Sciences
- First posted
- May 18, 2015
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy and safety of an intravenous treatment regimen of two doses of anifrolumab versus placebo in adult subjects with moderately to severely active, autoantibody-positive systemic lupus erythematosus (SLE).
Conditions
- Active Systemic Lupus Erythematosus
Interventions
AnifrolumabBiological
Anifrolumab IV administration every 4 weeks from Week 0 to Week 48 for a total of 13 doses
PlaceboDrug
Placebo IV administration every 4 weeks from Week 0 to Week 48
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants Who Achieved a Systemic Lupus Erythematosus (SLE) Responder Index ≥4 (SRI[4]) at Week 52 (Original Analysis With Restricted Medication Rules)Time frame: Week 52
Locations
145 sites in 18 countries. Site status is shown where the registry gives one.
Research Site
Birmingham, Alabama
Research Site
El Cajon, California
Research Site
La Jolla, California
Research Site
Los Alamitos, California
Research Site
Thousand Oaks, California
Research Site
Aurora, Colorado
Research Site
Aventura, Florida
Research Site
Miami, Florida
Research Site
Orlando, Florida
Research Site
Orlando, Florida
Research Site
Ormond Beach, Florida
Research Site
Plantation, Florida
Research Site
Tampa, Florida
Research Site
Vero Beach, Florida
Research Site
Decatur, Georgia
Research Site
Lawrenceville, Georgia
Research Site
Marietta, Georgia
Research Site
Boise, Idaho
Research Site
Idaho Falls, Idaho
Research Site
Baton Rouge, Louisiana
Research Site
Hagerstown, Maryland
Research Site
Hagerstown, Maryland
Research Site
Grand Rapids, Michigan
Research Site
Minneapolis, Minnesota
Research Site
Nashua, New Hampshire
Research Site
Freehold, New Jersey
Research Site
Great Neck, New York
Research Site
New Hyde Park, New York
Research Site
Charlotte, North Carolina
Research Site
Charlotte, North Carolina
Research Site
Raleigh, North Carolina
Research Site
Cleveland, Ohio
Research Site
Middleburg Heights, Ohio
Research Site
Oklahoma City, Oklahoma
Research Site
Tulsa, Oklahoma
Research Site
Philadelphia, Pennsylvania
Research Site
Pittsburgh, Pennsylvania
Research Site
Wyomissing, Pennsylvania
Research Site
Charleston, South Carolina
Research Site
Charleston, South Carolina
Showing 40 of 145 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.